Protective effect of exogenous matrix metalloproteinase-9 on chronic renal failure

Experimental and Therapeutic Medicine

Volumn 7, Issue 2, 2014, Pages 329-334

  Wang, Lei ^a   Wang, Jue ^a   Wang, Yong ^a   Fu, Qiang ^a   Lei, Yong Hua ^a   Nie, Zhi Yong ^b   Qiu, Jianxin ^a   Bao, Ting Yi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Center of Orthopedics and Trauma   (China)

Author keywords

Adenine; Chronic renal failure; MMP 9; TIMP 1

Indexed keywords

A 8626; ADENINE; CREATININE; GELATINASE B; PROTEIN HYDROLYSATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; KIDNEY FUNCTION; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84890522950     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1409     Document Type: Article

References (29)

1. Lenz O, Elliot SJ and Stetler-Stevenson WG: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11: 574-581, 2000.
2. Catania JM, Chen G and Parrish AR: Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292: F905-F911, 2007.
3. Cai G, Zhang X, Hong Q, et al: Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant 23: 1861-1875, 2008.
4. Hartleroad JY, Beharry KD, Hausman N, Stavitsky Y, Asrat T and Modanlou HD: Effect of maternal administration of selective cyclooxygenase (COX)-2 inhibitors on renal size, growth factors, proteinases, and COX-2 secretion in the fetal rabbit. Biol Neonate 87: 246-253, 2005.
5. Piedagnel R, Murphy G, Ronco PM and Lelongt B: Matrix metalloproteinase 2 (MMP2) and MMP-9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. J Biol Chem 274: 1614-1620, 1999.
6. Siefert SA and Sarkar R: Matrix metalloproteinases in vascular physiology and disease. Vascular 20: 210-216, 2012.
7. Rémy L: Current data on metalloproteinases, obligatory partners of tumor progression. Pathol Biol (Paris) 45: 759-765, 1997 (In French).
8. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
9. Tomita M, Koike H, Han GD, Shimizu F and Kawachi H: Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion. Clin Exp Nephrol 8: 17-26, 2004.
10. Carome MA, Striker LJ and Peten EP, et al: Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol 264: F923-F929, 1993.
11. Musiał K and Zwolińska D: Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones 16: 97-103, 2011.
12. Liu Y, Rajur K, Tolbert E and Dworkin LD: Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2024, 2000.
13. Rysz J, Banach M and Stolarek RA: Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 20: 444-452, 2007.
14. Chung AW, Yang HH, Sigrist MK, et al: Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 84: 494-504, 2009.
15. Nicholas SB, Yuan J, Aminzadeh A, Norris KC, Crum A and Vaziri ND: Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy. Am J Transl Res 4: 257-268, 2012.
16. Dai YQ, Jin DZ, Zhu XZ and Lei DL: Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci Res 55: 154-160, 2006.
17. Morishita Y, Ohnishi A and Watanabe M: Establishment of acute kidney injury mouse model by 0.75% adenine ingestion. Ren Fail 33: 1013-1018, 2011.
18. Kuroda T, Yoshida Y, Kamiie J, et al: Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol 8: 206-215, 2004.
19. González-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C and Montaño M: Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology 66: 196-204, 1998.
20. Uchio-Yamada K, Manabe N and Goto Y, et al: Decreased expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the kidneys of hereditary nephrotic (ICGN) mice. J Vet Med Sci 67: 35-41, 2005.
21. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS and Lian JD: Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 366: 243-248, 2006.
22. He W, Tan RJ, Li Y, et al: Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD. J Am Soc Nephrol 23: 294-304, 2012.
23. Duymelinck C, Dauwe SE, De Greef KE, et al: TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat. Kidney Int 58: 1186-1201, 2000.
24. Hörstrup JH, Gehrmann M, Schneider B, et al: Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 17: 1005-1013, 2002.
25. Suddek GM, El-Kenawi AE, Abdel-Aziz A and El-Kashef HA: Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity. Chemotherapy 57: 321-326, 2011.
26. Shibakawa A, Yudoh K, Masuko-Hongo K, Kato T, Nishioka K and Nakamura H: The role of subchondral bone resorption pits in osteoarthritis: MMP production by cells derived from bone marrow. Osteoarthritis Cartilage 13: 679-687, 2005.
27. Kim JY, Choeng HC, Ahn C and Cho SH: Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med J 50: 68-77, 2009.
28. Peng WH, Tien YC and Huang CY, et al: Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1. J Ethnopharmacol 127: 606-613, 2010.
29. Qin YH, Lei FY, Hu P, et al: Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Pediatr Nephrol 24: 1477-1486, 2009.